India may use FDA as model for bolstering its oversight

At one point, a top Indian regulator contended that India could not afford to establish the same level of expectations for its inspections of its domestic business as the U.S. did. But with FDA actions against Indian drugmakers taking a financial toll, the country is now rethinking that position. The Health Ministry and Central Drug Standards Control Organization (CDSCO), will work together on looking at the standards and guidelines of health regulators in other countries, with an emphasis on the U.S. model. FiercePharmaAsia story | More

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

CureVac has tapped Wacker to help produce 100 million doses of its mRNA-based COVID-19 vaccine at its Amsterdam facility.